News | April 02, 2009

Results of Two Studies on Counterpulsation Therapy to Promote Collateral Growth Presented at the ACC

April 2, 2009 - Vasomedical Inc. this week conducted two presentations on the beneficial effects of EECP external counterpulsation therapy at the 58th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando.

The external EECP counterpulsation therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen. Function of the endothelium, the inner lining of blood vessels throughout the body, is also improved, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, the company said.

The first presentation by Randy W. Braith, M.D., Richard C. Conti, M.D., and colleagues from the University of Florida in Gainesville demonstrated that EECP therapy significantly improves brachial flow-mediated dilation, reduces arterial stiffness, increases nitric oxide release, exercise duration and peak oxygen consumption while there are no significant changes in the control group with low pressure sham EECP treatment. The consistency of all parameters examined in this study involving non-invasive measurements of endothelial functions by a world-class team of scientists, researchers, and clinicians confirms that EECP therapy improves peripheral endothelial function and reduces arterial stiffness. These vascular adaptations decrease left ventricular afterload and myocardial oxygen demand, and increase anginal threshold in patients with refractory angina.

The second presentation by Steffen Gloekler, M.D., and colleagues from University Hospital in Bern, Switzerland showed EECP therapy promotes coronary collateral growth (arteriogenesis) in a single-blinded, sham-controlled study of 15 coronary artery disease (CAD) patients, treated for 30 hours at two-hours per daily session. Nine patients received EECP treatment with 300 mmHg of cuff inflation pressure (EECP group), six with 80 mmHg inflation pressure (sham group). Invasive coronary collateral assessment was performed at baseline and after EECP therapy using the Collateral Flow Index (CFI); a ratio of mean occlusive pressure determined invasively using a pressure guidewire distal to the balloon-occluded coronary artery and the mean aortic pressure. In the EECP group, CFI changed from 0.122 ± 0.06 to 0.210 ± 0.07, p=0.0002, and in the sham group from 0.165 ± 0.08 to 0.130 ± 0.06, p=0.04. The active EECP treatment induced a difference of CFI of 0.088 ± 0.07 versus –0.044 ± 0.07 in the sham group (p=0.00005). The study concluded that the clinical benefit of EECP for CAD patients might be explained by its arteriogenetic effect due to the increased laminar shear stress at the endothelial cell layer, improving endothelial function.

"The clinical effectiveness of EECP in the treatment of ischemic heart disease has been well established, but the multiple mechanisms of action (MOA) remain to be explored. The mounting evidence that EECP increases blood flow velocity and therefore the shear stress on the endothelium leading to improvement in endothelial function can now be recognized as one of the leading MOA. The two randomized-controlled studies presented during this ACC meeting provide definitive evidence to support the hypothesis that EECP improves endothelial function and enhances arteriogenesis by promoting collateral growth," Dr. Conti said.

For more information: www.acc.org, www.vasomedical.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init